VCP
CRBP icon

Verus Capital Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Verus Capital Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$10K Hold
63
– – ﹤0.01% 992
2019
Q4 		$10K Buy
+63
New +$9.31K ﹤0.01% 1124

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verus Capital Partners's CRBP Position: Q1 2020 in Review

Verus Capital Partners held its Corbus Pharmaceuticals (CRBP) position steady in Q1 2020 at 63 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #992.

Verus Capital Partners first reported a position in CRBP in Q4 2019 and has held it in 2 quarters since. 111 funds tracked by Wall St. Rank hold CRBP as of Q1 2020.

  • Verus Capital Partners held 63 shares of Corbus Pharmaceuticals worth $10K as of Q1 2020.
  • Verus Capital Partners left its Corbus Pharmaceuticals share count unchanged in Q1 2020.
  • Corbus Pharmaceuticals made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #992 holding.
  • Verus Capital Partners first reported a position in Corbus Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • 111 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.